Dow Jones 30 Stocks SEC Filings — October 13, 2026

13-10-2026

UnitedHealth Group reported Q3 2026 revenues of $112.7 Billion, down from $113.2 Billion a year earlier, while earnings from operations rose to $6.6 Billion from $4.3 Billion and EPS was $4.56 ($4.69 adjusted). The company raised full-year 2026 EPS guidance to at least $19.50 (adjusted at least $20.50), but UnitedHealthcare membership and Optum Health revenue declined year over year, and Q3 MCR benefited from $610 Million of favorable prior-period reserve development.

• · Net medical reserve development of $610 million favorably impacted the Q3 2026 MCR and is not indicative of run-rate performance.
• · Optum Health revenue fell 10% YoY as value-based care patients were exited in markets lacking sufficient clinician presence.
• · UnitedHealthcare membership is shrinking across segments: Employer & Individual down 165,000, Community & State down 85,000, and Medicare Advantage seniors down 935,000 since year-end 2025.
• · Optum Rx adjusted scripts fell from 414 million to 393 million YoY due to membership declines.
• · Debt-to-capital ratio rose to 41.7% from 41.2% in Q2 2026, versus a target of approximately 40.0% by year-end.
• · Medicare & Retirement revenues declined 2.3% YoY due to membership and product mix changes.
• · Full-year guidance was raised to at least $19.50 EPS (adjusted at least $20.50), reflecting experience through Q3 2026.

13-10-2026

JPMorgan Chase reported third-quarter 2026 net income of $15.3 billion ($5.57 per diluted share), down 28% QoQ but up 6% YoY, and managed net revenue of $50.9 billion, up 8% YoY. Results were held down by a $658 million pre-tax net investment securities loss in Corporate; excluding this item, net income was $15.8 billion ($5.75 per share). Performance was mixed: CIB and CCB grew strongly YoY while Fixed Income Markets, Corporate and Home Lending declined.

• · Fixed Income Markets revenue fell 4% YoY, driven by lower Commodities, Rates, Credit and Public Finance revenue
• · Home Lending net revenue declined 3% QoQ and 5% YoY on lower production revenue
• · Investment Banking fees declined 8% QoQ despite 14% YoY growth, reflecting moderating client activity during the quarter
• · Net interest income excluding Markets rose 6% YoY, while total net interest income rose 13%, aided by higher deposit and card balances
• · Management reduced share repurchases this quarter in line with the stated capital hierarchy
• · Net charge-offs fell $389 million YoY, driven by Wholesale
• · Management flagged large fiscal deficits, sticky inflation, elevated asset prices, rising rates and geopolitical risks as forces shifting beneath the surface

13-10-2026

Goldman Sachs reported third quarter 2026 net revenues of $18.68 billion (up 23% YoY but down 8% QoQ) and net earnings of $5.29 billion, with diluted EPS of $17.01 versus $12.25 a year earlier and $20.98 in Q2 2026. Growth was driven by Global Banking & Markets (up 32% YoY) and Asset & Wealth Management (up 14% YoY), while Platform Solutions fell 72% YoY and Global Banking & Markets declined 13% QoQ, and Q3 operating expenses rose 20% YoY.

• · Net revenues in Global Banking & Markets declined 13% QoQ, while Equities revenues fell 13% QoQ and FICC fell 24% QoQ
• · Investment banking fees backlog decreased versus end of Q2 2026 and slightly versus end of 2025
• · Asset & Wealth Management Investments revenue fell 89% YoY due to net markdowns in debt investments; Private banking and lending fell 22% YoY
• · Effective tax rate rose to 20.4% for nine months 2026 from 18.5% in the first half of 2026
• · Americas share of net revenues fell to 63% in Q3 2026 from 66% a year earlier, while Asia rose to 20% from 13%
• · Quarterly dividend of $5.00 per common share declared for payment December 30, 2026 (record date December 2, 2026)
• · Global core liquid assets averaged $574 billion in Q3 2026, up from $555 billion in Q2 2026

13-10-2026

Johnson & Johnson reported Q3 2026 reported sales of $25,399 Million, up 5.9% YoY, with operational growth of 6.0% and adjusted operational growth of 6.1%. GAAP net earnings fell 95.9% to $210 Million (EPS $0.09) due to a one-time special charge for the proposed talc litigation resolution, while adjusted EPS declined 7.5% to $2.59 and adjusted net earnings fell 6.8% to $6,339 Million, both reflecting M&A-related impacts. Management raised full-year 2026 adjusted operational EPS guidance midpoint to $11.00 and adjusted EPS guidance midpoint to $11.10, while estimated reported sales guidance midpoint is $101.2 Billion (+7.4%).

• · STELARA caused an approximate 690 basis point drag on Innovative Medicine growth in Q3 2026
• · Q3 2026 included a one-time special charge for the proposed ovarian talc litigation resolution, the primary driver of the GAAP earnings decline
• · Q3 2026 Q3 EPS of $0.09 versus $2.12 in Q3 2025 on a GAAP basis
• · Q3 2026 MedTech growth of 2.5% was modest, supported by electrophysiology, Shockwave, contact lenses, and trauma
• · Management targets double-digit growth by the end of the decade
• · Regulatory milestones include FDA approval of IMAAVY for warm autoimmune hemolytic anemia, FDA market authorization of OTTAVA, and FDA Priority Review for RYBREVANT FASPRO in head and neck cancer
• · Jennifer Taubert is retiring and Tom Cavanaugh will become EVP, Worldwide Chairman Innovative Medicine effective September

13-10-2026

Procter & Gamble's Board declared a quarterly dividend of $1.0885 per share on Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock, payable on or after November 16, 2026, to holders of record on October 23, 2026. The company also reported, per preliminary voting results, that all twelve Director nominees were elected at the Annual Meeting of Shareholders. The filing is a Regulation FD disclosure furnishing Exhibit 99.1 (the dividend news release); it contains no financial results, guidance, or negative developments.

• · Common Stock dividend record date is October 23, 2026, with payment on or after November 16, 2026
• · Series A and Series B ESOP Convertible Class A Preferred Stock holders of record as of the start of business on October 23, 2026
• · Voting results are preliminary and subject to certification

13-10-2026

Merck & Co. announced that Paul J. Diaz, managing partner at Cressey & Company, will join the Board of Directors effective November 1, 2026, bringing the board to 14 members. He will stand for shareholder election in May 2027. The filing is a board appointment press release with no financial results, guidance, or quantitative performance disclosure.

• · Diaz previously served as president and CEO of Myriad Genetics and as president and CEO of Kindred Healthcare
• · Diaz currently sits on the Board of Centene Corporation and the Board of Trustees of Johns Hopkins Medicine
• · Diaz holds a bachelor's degree in finance and accounting from American University and a J.D. from Georgetown University

13-10-2026

EVP, Global Sales Tuszik Oliver had withheld for taxes 2,259.591 Common Stock at $118.39 (~$268K). Tuszik Oliver holds 230,690.08 shares after the transaction.

• · EVP, Global Sales Tuszik Oliver had withheld for taxes 2,259.591 Common Stock at $118.39 (~$268K)

13-10-2026

EVP, Worldwide Field Ops Parker Nicholas P. was awarded 160,418 Common Stock. This amends a previously filed Form 4. Parker Nicholas P. holds 160,418 shares after the transaction.

• · EVP, Worldwide Field Ops Parker Nicholas P. was awarded 160,418 Common Stock